Spots Global Cancer Trial Database for monoclonal antibody
Every month we try and update this database with for monoclonal antibody cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist | NCT00001475 | Acquired Immuno... HIV Infection | IL-2 plus Anti-... | - | National Institutes of Health Clinical Center (CC) | |
| Avelumab for People With Recurrent Respiratory Papillomatosis | NCT02859454 | Recurrent Respi... Juvenile Laryng... Laryngeal Papil... Respiratory Pap... Human Papilloma... | Avelumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | NCT03041701 | Rhabdomyosarcom... Rhabdomyosarcom... Rhabdomyosarcom... | Dasatinib Dasatinib Ganitumab | 2 Years - | National Institutes of Health Clinical Center (CC) | |
| Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer | NCT02875613 | Nasopharyngeal ... | Avelumab | 18 Years - | University of California, San Diego | |
| A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma | NCT01472198 | Pancreatic Canc... | Simtuzumab Gemcitabine Placebo to matc... | 18 Years - | Gilead Sciences | |
| Fresolimumab and Radiotherapy in Metastatic Breast Cancer | NCT01401062 | Metastatic Brea... | Fresolimumab Radiation Thera... | 18 Years - | Weill Medical College of Cornell University | |
| HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy | NCT01370239 | Breast Cancer | Hu3S193 | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients | NCT02574598 | Carcinoma, Non-... | MK-3475 Docetaxel | 18 Years - 90 Years | Instituto Nacional de Cancerologia de Mexico | |
| A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors. | NCT05203601 | Tumor | SIBP-03 | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors | NCT04678921 | Solid Tumor Metastatic Canc... Advanced Cancer | TJ210001 | 18 Years - 99 Years | I-Mab Biopharma US Limited | |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | NCT04134936 | Diffuse Large B... | Tafasitamab Tafasitamab plu... | 18 Years - | MorphoSys AG | |
| A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT01266811 | Multiple Myelom... | Placebo, Velcad... Siltuximab, Vel... | 18 Years - | Centocor, Inc. | |
| Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma | NCT02401542 | Locally Advance... Urinary Bladder... Urological Dise... | Vofatamab Docetaxel Placebo | 18 Years - | Rainier Therapeutics | |
| Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma | NCT00775502 | Multiple Myelom... | BIW-8962 | 18 Years - 75 Years | Kyowa Kirin Co., Ltd. | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | NCT04739813 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | obinutuzumab prednisone Revlimid Polatuzumab ibrutinib venetoclax | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia | NCT01059786 | Hairy Cell Leuk... | Pentostatin Rituximab Bendamustine Acetaminophen Diphenhydramine Epinephrine Antihistamines Corticosteroids Bronchodilators Intravenous (IV... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | NCT06149481 | Metastatic Colo... | Retifanlimab Therapeutic CEA... N-803 SX-682 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | NCT00089765 | Von Hippel-Lind... | Ranibizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma | NCT00600054 | Recurrent Diffu... | nimotuzumab (an... | 3 Years - 18 Years | YM BioSciences | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| Expanded Access Study of Iodine-131 Anti-B1 Antibody | NCT00022958 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma | NCT02983006 | Melanoma | DS-8273a Nivolumab | 18 Years - | NYU Langone Health | |
| Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors | NCT00091806 | Tumors Oncology Solid Tumors | panitumumab (AB... Panitumumab | 18 Years - | Amgen | |
| A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients | NCT04124497 | Multiple Myelom... Deletion 17P Sy... | Daratumumab Pomalidomide Dexamethasone | 18 Years - | Fondazione EMN Italy Onlus | |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00401843 | Multiple Myelom... | Siltuximab Bortezomib Placebo Dexamethasone | 18 Years - 99 Years | Janssen Research & Development, LLC | |
| Anti-TGF-beta Therapy in Patients With Myelofibrosis | NCT01291784 | Myelofibrosis Primary Myelofi... Polycythemia Ve... Post-essential ... | monoclonal anti... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia | NCT02353143 | Recurrent Adult... Acute Myeloid L... | MEN1112 | 18 Years - | Menarini Group | |
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | NCT03041701 | Rhabdomyosarcom... Rhabdomyosarcom... Rhabdomyosarcom... | Dasatinib Dasatinib Ganitumab | 2 Years - | National Institutes of Health Clinical Center (CC) | |
| CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers | NCT00822809 | Cancer Neoplasms Carcinoma Malignant Ascit... | Catumaxomab Prednisolone | 18 Years - | Neovii Biotech | |
| A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma | NCT00199342 | Stage IV Melano... | KW-2871 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Expanded Access Study of Iodine-131 Anti-B1 Antibody | NCT00022958 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | NCT04824092 | Diffuse Large B... | Tafasitamab Lenalidomide Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tafasitamab pla... Lenalidomide pl... | 18 Years - 80 Years | MorphoSys AG | |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | NCT06149481 | Metastatic Colo... | Retifanlimab Therapeutic CEA... N-803 SX-682 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | NCT01025206 | Multiple Myelom... | BI-505 | 18 Years - | BioInvent International AB | |
| GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies | NCT04824794 | Relapsed or Ref... Diffuse Large B... Acute Myeloid L... | GEN3014 Daratumumab | 18 Years - | Genmab | |
| A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma | NCT01219010 | Monoclonal Gamm... Multiple Myelom... Plasma Cell Neo... | Siltuximab | 18 Years - | Janssen Research & Development, LLC | |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | NCT06147037 | Advanced Solid ... Metastatic Colo... Head and Neck S... Non-small Cell ... Pancreatic Duct... | FPI-2053 [111In]-FPI-210... [225Ac]-FPI-206... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy | NCT01370239 | Breast Cancer | Hu3S193 | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma | NCT00061048 | Acute T-Cell Le... | Alemtuzumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | NCT04824092 | Diffuse Large B... | Tafasitamab Lenalidomide Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tafasitamab pla... Lenalidomide pl... | 18 Years - 80 Years | MorphoSys AG | |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00401843 | Multiple Myelom... | Siltuximab Bortezomib Placebo Dexamethasone | 18 Years - 99 Years | Janssen Research & Development, LLC | |
| A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies | NCT05253105 | Previously Trea... Malignancies | TAB006 Toripalimab | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | NCT03223610 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | Venetoclax Ibrutinib Prednisone Obinutuzumab Revlimid (lenal... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ponatinib for Advanced Medullary Thyroid Cancer | NCT01838642 | Thyroid Neoplas... | Ponatinib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00401765 | Prostatic Neopl... | CNTO 328 Docetaxel | 18 Years - | Centocor, Inc. | |
| A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | NCT02821754 | Biliary Tract N... Liver Cancer Hepatocellular ... Cholangiocarcin... Bile Duct Cance... | Durvalumab Tremelimumab Trans-arterial ... Radiofrequency ... Cryoablation | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma | NCT01445392 | Mesothelioma | Multicycle SS1P Pemetrexed Cisplatin Single cycle SS... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma | NCT04301778 | Unresectable In... | Durvalumab SNDX-6352 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL | NCT00274742 | Non-Hodgkin's L... | Blinatumomab (M... | 18 Years - | Amgen Research (Munich) GmbH | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia | NCT00022880 | Chronic Lymphoc... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer | NCT00147537 | Carcinoma, Non-... | CP-751,871 paclitaxel carboplatin CP-751,871 paclitaxel carboplatin erlotinib | 18 Years - | Pfizer | |
| A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma | NCT00199342 | Stage IV Melano... | KW-2871 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT04445701 | Multiple Myelom... | AO-176 AO-176 + Dex AO-176 + Dex + ... | 18 Years - | Arch Oncology | |
| Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy | NCT01463059 | Rheumatoid Arth... | Placebo Olokizumab 60 m... Olokizumab 120 ... Olokizumab 240 ... | 20 Years - | UCB Pharma | |
| The Effect of TRA-8 on Ovarian Cancer Tissue | NCT00711932 | Ovarian Cancer | 19 Years - | University of Alabama at Birmingham | ||
| Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | NCT02311361 | Pancreatic Neop... Pancreatic Canc... Cancer of Pancr... Cancer of the P... Pancreas Cancer | Durvalumab Tremelimumab Sterostatic bod... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| HMBD-001 in Advanced HER3 Positive Solid Tumours | NCT05057013 | Bladder Cancer Triple Negative... Castration-resi... Cervical Cancer RAS Wild Type C... Endometrial Can... Gastric Cancer Hepatocellular ... Melanoma Non-small Cell ... Oesophageal Can... Ovarian Cancer Pancreatic Canc... Squamous Cell C... | HMBD-001 | 16 Years - | Cancer Research UK | |
| Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer | NCT00493857 | Colorectal Canc... | Nimotuzumab Hum... Nimotuzumab | 18 Years - | YM BioSciences | |
| A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer | NCT01911273 | Carcinoma, Hepa... | PF-03446962 Best Supportive... Placebo Best Supportive... | 18 Years - | Pfizer | |
| Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom | NCT03413579 | Cervical Cancer | Nimotuzumab ( h... Placebo | 18 Years - 75 Years | El Kendi Pharmaceuticals Manufacturing Company | |
| GRN1005 for Brain Metastases From Breast or Lung Cancer | NCT01679743 | Breast Cancer Lung Neoplasms Breast Neoplasm... Lung Cancer | Trastuzumab GRN 1005 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Ponatinib for Advanced Medullary Thyroid Cancer | NCT01838642 | Thyroid Neoplas... | Ponatinib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma | NCT00813605 | Metastatic Colo... | FOLFIRI AMG 655 Placebo AMG 479 | 18 Years - | NantCell, Inc. | |
| Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas | NCT00051675 | Adenocarcinoma | ING-1(heMAb) | 18 Years - | XOMA (US) LLC | |
| Fresolimumab and Radiotherapy in Metastatic Breast Cancer | NCT01401062 | Metastatic Brea... | Fresolimumab Radiation Thera... | 18 Years - | Weill Medical College of Cornell University | |
| A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants | NCT05909852 | Adalimumab | ABP 501-HCF ABP 501-LCF | 18 Years - 55 Years | Amgen | |
| Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia | NCT01829711 | Leukemia, Hairy... | Moxetumomab pas... IV Bag Protecta... | 18 Years - 100 Years | MedImmune LLC | |
| Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist | NCT00001475 | Acquired Immuno... HIV Infection | IL-2 plus Anti-... | - | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | NCT06149481 | Metastatic Colo... | Retifanlimab Therapeutic CEA... N-803 SX-682 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | NCT00402181 | Multiple Myelom... | Siltuximab Dexamethasone | 18 Years - | Centocor, Inc. | |
| A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors. | NCT05203601 | Tumor | SIBP-03 | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | NCT01206049 | Cholangiocarcin... | Gemcitabine Oxaliplatin Capecitabine Panitumumab Bevacizumab | 18 Years - | Vejle Hospital | |
| Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia | NCT03805932 | Hairy Cell Leuk... | Moxetumomab Pas... Rituximab Ruxience Dexamethasone Acetaminophen Diphenhydramine Famotidine Aspirin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | NCT01025206 | Multiple Myelom... | BI-505 | 18 Years - | BioInvent International AB | |
| TRC105 for Liver Cancer That Has Not Responded to Sorafenib | NCT01375569 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... | TRC105 | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | NCT03841110 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small Cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | FT500 Nivolumab Pembrolizumab Atezolizumab Cyclophosphamid... Fludarabine IL-2 | 18 Years - | Fate Therapeutics | |
| Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer | NCT00142415 | Metastatic Rena... | 111-In-DOTA-cG2... 177-Lu-DOTA-cG2... | 18 Years - | Ludwig Institute for Cancer Research |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
